Detalles de la búsqueda
1.
Structured benefit-risk assessment for enoxaparin, in the context of its label extension, for the extended treatment of deep vein thrombosis and pulmonary embolism, and prevention of its recurrence in patients with active cancer.
Pharmacoepidemiol Drug Saf
; 33(5): e5795, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38680090
Resultados
1 -
1
de 1
1
Próxima >
>>